| INTRODUCTION
Irritable bowel syndrome (IBS) is a functional bowel disorder characterised by recurrent abdominal pain and altered bowel habits, with these symptoms persisting for at least 6 months. 1, 2 It affects [10] [11] [12] [13] [14] [15] percent of the population, 3 but the aetiology and underlying pathophysiological mechanisms are poorly understood, resulting in suboptimal treatment options and responses. 4 IBS has a significant impact on the quality of life 5 and is also an important cause of healthcare seeking and work absenteeism. 6 Taken together, this is a problem to both the individuals' well-being and to society through loss of productivity and high healthcare costs. 7 There is a significant overlap with other functional gastrointestinal disorders, and the different functional gastrointestinal disorders may be viewed as parts of a continuum of functional disorders. 8 IBS is currently divided into subtypes based on the predominant stool consistency according to the Rome criteria: 1, 2 
IBS with constipation (IBS-C), IBS with diarrhoea (IBS-D), IBS with mixed bowel habits (IBS-M) and unsubtyped IBS
(IBS-U). However, other gastrointestinal (GI) symptoms, such as abdominal pain, bloating and overlapping upper GI symptoms, are also of importance for decisions about management. 9 It is well-known that patients with IBS often show psychiatric comorbidities such as anxiety and depression, [9] [10] [11] but may also present with multiple, medically unexplained extraintestinal symptoms. 12, 13 Moreover, the presence of extraintestinal and psychological symptoms affects the outcome in patients with IBS, which highlights their importance for clinical management decisions. 12, 14, 15 However, despite their importance, these symptoms are not included in the currently recommended subtyping of patients.
The complex combination of symptoms can be understood by viewing IBS as a disturbance of the brain-gut axis, a bi-directional communication network between central and enteric regulation systems. 8 This system constitutes a physiological framework which explains the interaction of peripheral mechanisms and psychosocial factors through neural (autonomic) and humoral pathways. Despite the growing knowledge of the nature of brain-gut interactions, it remains unclear how the mechanisms underlying the different features of IBS interact and why there is such a strong heterogeneity between IBS patients.
In this study, we hypothesise that IBS consists of subgroups of patients, which can be characterised by a combination of different (groups of) symptoms commonly found in patients with IBS. Our aim was therefore to identify subgroups of IBS patients based on a combination of GI and extraintestinal somatic symptoms, as well as psychological features.
| MATERIALS AND METHODS

| Study cohort
Adult patients (≥18 years) meeting the Rome III criteria for IBS 1 were recruited at the out-patient clinic of Sahlgrenska University
Hospital, Gothenburg, Sweden. During an interview, the medical history, including duration of IBS symptoms and possible post-infectious origin, was recorded. The diagnosis was based on clinical presentation and additional investigations if considered necessary by the gastroenterologist (HT or MS). However, the vast majority of patients were referred from primary care and had already undergone sufficient investigations to rule out other diagnoses. The patients also completed a two-week stool diary using the Bristol Stool Form scale, 16 which was used to determine the IBS subtypes based on the predominant stool consistency as recommended by the Rome III committee. 1 If data from the stool diaries were incomplete or missing (n=27), patients were subgrouped by the treating physician based on an evaluation of the patients' clinical history and detailed assessment of their bowel habits during the clinical interview. All participants refrained from medication affecting pain, motility or stool form as well as from psychotropic medication during the time of participation in this study. Exclusion criteria included abnormal results on standard screening laboratory tests, severe psychiatric, systemic or other GI diseases, history of drug or alcohol abuse, and the inability to reliably respond to questionnaires in Swedish. All patients gave their written consent to participate after verbal and written information, and the study protocol was approved by the Regional Ethical
Review Board in Gothenburg prior to the start of patient inclusion.
| Questionnaires
We used validated self-report instruments for somatic symptom assessment as well as for psychological features and extended these measures by a 7-day bowel habit diary to get detailed information about stool form and frequency. 17 
| Irritable bowel syndrome symptoms
The Gastrointestinal Symptom Rating Scale (GSRS-IBS) 18 is a 13-item questionnaire used to assess GI symptoms typically present in IBS.
All 13 questions were used as individual items, in order to capture the symptom profile in detail. The questions of the GSRS-IBS are scored on a seven-point Likert scale from 1="No discomfort at all" up to 7="Very severe discomfort", and cover the following symptoms: "abdominal pain", "pain/discomfort relieved by defecation", "bloating", "passing gas", "visible abdominal swelling (abdominal distention)", "constipation" (referring to infrequent stools), "hard stools", "diarrhoea" (referring to frequent stools), "loose stools", "urgency", "incomplete bowel emptying", "early satiety", "fullness".
| Bristol Stool Form diary
The patients were asked to register every bowel movement over two weeks in a diary and characterise the stool frequency and consistency of each bowel movement by use of the Bristol Stool Form scale. 16 This scale determines the stool form in categories ranging from 1 to 7, hard and lumpy stools [1] -watery stools [7] , with a normal stool form being defined as categories 3-5. For the Rome IIIbased subtyping, 1 the whole two-week period was analysed, whereas for the statistical modelling, stool form ratings and stool frequency were averaged over a 7-day period to avoid balancing out the scores of subjects with alternating hard and loose stools.
| Extraintestinal somatic symptoms
The Patient Health Questionnaire (PHQ) 15 19 is a validated measure assessing the severity of somatic symptoms, often referred to as "somatisation". We have used the 12 items of this questionnaire that measure extraintestinal symptoms (PHQ-12) as a representation of non-GI or extraintestinal somatic symptoms. 20 Each question uses a scale from 0="not bothered at all" to 2="bothered a lot". We have used each question as a single-item symptom registration in our model. The questions measure the following symptoms: "back pain", "pain in arms, legs or joints", "menstrual cramps or other problems with the period", "pain or problems during sexual intercourse", "headaches", "chest pain", "dizziness", "fainting spells", "feeling the heart pound or race (palpitation)", "shortness of breath", "feeling tired or having low energy (tiredness)" and "trouble sleeping".
| Psychological symptoms
The Hospital Anxiety and Depression (HAD) scale is a measure of psychological distress and was developed for use in medical outpatients rather than in psychiatric patients. 21 It consists of 14 items, each using a 4-grade Likert scale (0-3), with subscales for severity of anxiety (seven items) and depression (seven items) symptoms. The severity is rated on a scale from 0 to 21 with increasing severity reflected by a higher score. Commonly, a score above 10 is used as a cut-off for clinically relevant anxiety or depression and scores of 8-10 are considered borderline cases. The two subscales (0-21) were used as continuous measures of anxiety or depression symptom severity in our model, while the cut-offs were used to identify clinically relevant cases (for descriptive purposes).
| Severity of IBS
The IBS-severity scoring system (IBS-SSS) 22 is a questionnaire commonly used to assess the perceived severity of IBS symptoms.
Scores range from 0 (no symptoms) to 500 (maximum severity) and patients can be divided into subgroups of mild (75-175), moderate (175-300) or severe (>300) IBS symptoms. We used this questionnaire to describe the overall severity of IBS in our patient cohort and the subgroups identified based on the mixture model, but the questionnaire data were not part of the variables entered into the mixture model.
| Statistical analysis
Statistical analyses were performed using R (version 3.1.2 -"Pumpkin Helmet") 23 and SPSS (IBM SPSS Statistics for Linux, Version 22.0, Armonk, NY, USA; 2013). Missing data were imputed using a multivariate approach implemented in the R package (MissMDA) as described in Josse et al. 24 After imputation, the data were log transformed due to skewness in the data distribution.
To identify subgroups in the sample of IBS patients, we deployed a Gaussian finite mixture model fitted by an expectation maximisation algorithm as implemented in the Mclust package of R. 25 Mixture modelling is a statistical strategy used to identify naturally occurring subpopulations (latent classes) in a pooled population based on a probabilistic model. 26, 27 It assumes that the analysed dataset is a mixture of observations from different latent classes or clusters (which we will refer to as "subgroups" in this The resulting subgroups were compared with respect to symptom profiles of the input variables using analysis of variance (ANOVA) followed up by pairwise comparisons of all subgroups using post hoc t tests and Tukey correction for multiple testing. To describe the respective group profiles, the average symptom scores within each group were compared to the overall average and termed relative to this (eg the term "high comorbidities" was used if the group average for extraintestinal somatic and psychological symptoms was higher than overall average, the term "low comorbidities"
if it was lower than overall average. The descriptors for individual symptoms were used accordingly). The groups were additionally compared regarding demographic descriptors, IBS severity, 22 presence of clinically relevant anxiety or depression, 21 and Rome III sub- 3 | RESULTS
| Descriptive data of the study cohort
In this study, we analysed data from 172 patients with IBS. Among these, 119 were women (69%), and the mean age was 33. | 531
About half of the patients (52%) had severe IBS based on the IBS-SSS, 22 and an IBS-duration of more than 10 years (47% Table S1 .
| Mixture model subgroups
The maximum Bayesian Information Criterion our model was The last two groups were characterised by a mixed profile of GI symptoms with a heterogeneous mix of high extraintestinal somatic symptoms, and a group characterised by overall low severity of symptoms, respectively. To highlight and visually compare the groupspecific symptom profiles, we generated a radar plot ( Figure 2A ) and a heatmap ( Figure 2B ) of the scaled and normalised single-item symptom scores showing the profiles described above in more detail.
Differences between the groups were significant for all symptoms in the ANOVA test after Stepdown Bonferroni correction. Details of the post hoc analyses are shown in Table S1 .
| Constipation-predominant groups
The specific symptom profiles of the two constipation-predominant groups are shown in Figures 3A,B . Both groups scored low on diarrhoea-related symptoms. The group average, based on absolute values, for the different symptoms with post hoc analysis is given in Table S1 .
| Constipation-low comorbidities
The constipation-low comorbidities group ( Figure 3A) showed above average values for the following individual GI symptoms: "constipation", "hard stools", "abdominal distention", "bloating", "passing gas"
and "pain relieved by bowel movement", and below average values for all other symptoms (GI, extraintestinal somatic and psychological).
| Constipation-high comorbidities
The constipation-high comorbidities group ( Figure 3B ) on the other hand showed a broader GI symptom profile with above average values for "constipation", "hard stools", "abdominal distention", "incomplete bowel emptying" as well as the dyspeptic symptoms "early satiety" and "fullness". Additionally, this group showed above average scores for "anxiety" and "depression", as well as all extraintestinal somatic symptoms measured by the PHQ-12, except for "fainting spells". The highest relative scores for extraintestinal somatic symptoms were seen for "shortness of breath" and "trouble sleeping".
| Diarrhoea-predominant groups
The specific symptom profiles of the two diarrhoea-predominant groups are shown in Figures 3C,D . Both groups scored low on constipation-related symptoms. The group average, based on absolute values, for the different symptoms with post hoc analysis is given in Table S1 .
| Diarrhoea-low comorbidities
The diarrhoea-low comorbidities group ( Figure 3C ) showed above average values for the following individual GI symptoms: "diarrhoea", "loose stools", "urgency", "stool form" and "stool frequency". This group showed average scores for most extraintestinal symptoms and "depression", and below average for "trouble sleeping", "shortness of breath", "fainting spells", "palpitations", "intercourse-related pain" and "anxiety". 
| Diarrhoea-pain-high comorbidities
The diarrhoea-pain-high comorbidities group ( Figure 3D ) on the other hand showed diarrhoea-related and pain-related GI symptoms characterised by above average values for "abdominal pain", "pain relieved by defecation", "diarrhoea", "loose stools" and "urgency".
This group additionally showed above average scores for 'anxiety'
and 'depression' and all extraintestinal somatic symptoms measured by the PHQ-12. The highest relative scores for extraintestinal somatic symptoms were reached by "dizziness", "shortness of breath"
and "headaches".
| Mixed symptom groups
The specific symptom profiles of the two mixed symptom groups are shown in Figures 3E,F . Both groups were characterised by a mixed profile of GI and extraintestinal somatic and psychological symptoms, while differing regarding symptom severity. The group average, based on absolute values, for the different symptoms with post hoc analysis is given in Table S1 .
| Mixed GI-high Comorbidities
The mixed GI-high comorbidities ( Figure 3E ) was characterised by above average values for virtually all GI symptoms, including both constipation-and diarrhoea-related symptoms. The group also showed above average scores for the psychological symptoms "anxiety" and "depression" and some extraintestinal somatic symptoms, with above average scores for "tiredness", "sleep-related problems", "palpitations", "dizziness" and "chest pain", but average or lower than average scores for the other PHQ-12 symptoms.
| Mild overall symptoms
The mild overall symptoms group ( Figure 3F ) was characterised by below average scores for all symptoms (GI, extraintestinal somatic and psychological) except "stool form" which was around average.
| Other characteristics of the groups
Most groups showed a predominance of female patients (v 2 : P<.01, Table S2 ). The diarrhoea-pain-high comorbidities group consisted of only females, whereas the mild overall symptoms group consisted of only 48% females. The mean age of the groups ranged from 30.3 to 36.8 years, with no statistically significant difference between the groups (Table S2) . Moreover, there were no significant group differences with respect to IBS symptom duration or possible post infectious origin of symptoms (Table S2 ). There was a significant difference between the groups regarding severity based on IBS-SSS (v 2 : P<.01, F I G U R E 2 A, Symptom profiles of the six subgroups identified by the mixture model analysis. GI symptoms are shown on the right, extraintestinal somatic and psychological symptoms on the left. The group averages are standardised and plotted in relation to the cohort average that is normalised to zero. Values above zero are thus above average, by which the group symptom profile can be determined. Since all individuals here are IBS patients with GI symptoms, this figure clearly shows that there is an overlap between the groups, but specific combinations of symptoms characterise the respective groups (see also Figure 3 for detailed visualisation of the respective group profiles). The scores for "fainting spells" were removed in the graph to improve the resolution of important details of group differences (The symptom "fainting spells" was only present in one group (diarrhoea-pain-high comorbidities), possibly an artefact resulting from being reported only by a small number of patients, which produced a large spike during the scaling process); an additional smaller graph showing all symptoms including "fainting spells" is shown as well. B, Heatmap of the symptom profiles of the six subgroups identified by the mixture model analysis. The darkness of the shading is proportional to the respective group-specific severity of each symptom With the new Rome IV diagnostic criteria published recently, it will also be interesting to see whether these groups are present in cohorts defined based on Rome IV, and test whether the more strict inclusion criteria of Rome IV relative to Rome III may alter or generate a higher resolution of symptom associations. Several authors 33, 34 have discussed the necessity of screening patients for extraintestinal somatic symptoms for an improved clinical judgment and more precise diagnosis. Our findings support the clinical importance of considering a broader combination of symptoms when choosing management strategies for the individual patient by showing the existence of subgroups with and without such additional symptoms, which is in line with both previous studies highlighting the importance of a spectrum of GI symptoms in IBS 35 and similarly in functional dyspepsia, 36 as well as the MDCP concept proposed by the Rome committee. 32 However, it is known that predominant bowel habits in IBS tend to fluctuate over a period of time, [37] [38] [39] There are further limitations to this study, besides its cross-sectional nature addressed above. While our study is based on a large, well-phenotyped patient cohort, when interpreting the results, it is important to consider that all patients were recruited from a secondary/tertiary referral centre, which could introduce a potential recruitment bias towards more severe symptoms. However, only about half the patients included were classified as severe IBS patients; clinically relevant psychological comorbidities were only present in a subset of the sample; and the symptom duration varied substantially within the cohort. These characteristics of our cohort, together with the fact that most subjects were referred from their primary care physician, but are normally managed in primary care, suggest that we have a sample that quite well represents the general and heterogeneous IBS population. and to differentiate between IBS-C and functional constipation. 41 In addition to this, we have applied strict criteria in controlling for multiple testing. Taken together, the statistical approach is designed to minimise the risk of spurious findings being reported by this exploratory analysis.
In conclusion, we have demonstrated that it is possible to subgroup IBS patients based on a combination of GI, psychological and extraintestinal somatic symptoms that are common in patients with IBS, which may be of relevance for clinical management, as well as POLSTER ET AL.
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for research. The potential clinical implications may be that our results highlight the importance of screening for extraintestinal somatic and psychological comorbidities in patients with IBS, as patients with these comorbidities may benefit more from interventions targeting central mechanisms including psychiatric comorbidities 34, 42 and "somatisation", 14, 15 while those without such additional symptoms may benefit from interventions targeting GI symptoms more specifically. However, the predictive capabilities regarding treatment outcome and long-term stability of group membership remain to be explored in future studies. The research implications of this study are the importance of detailed clinical phenotyping of participants, to reduce noise in the data due to heterogeneity and potential dissimilarity of patients when studying underlying mechanisms which might conceal significant findings. The next steps are to compare these naturally occurring groups regarding pathophysiological mechanisms, and to explore the stability of this grouping over time.
